Kenji Nakahama - Department of Pulmonary Medicine, Ishikiriseiki Hospital

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 32 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients with Hemodialysis: A Nationwide Retrospective Cohort Study

Kenji Sawa,Yasutaka Ihara,Takumi Imai,Akira Sugimoto,Hiroaki Nagamine,Koichi Ogawa,Kenji Nakahama,Yoshiya Matsumoto,Yoko Tani,Hiroyasu Kaneda,Shigeki Mitsuoka,Tomoya Kawaguchi,Ayumi Shintani

CLINICAL LUNG CANCERno. 2 (2024)

引用0浏览0WOS引用

Derived Neutrophil-to-lymphocyte Ratio Has the Potential to Predict Safety and Outcomes of Durvalumab after Chemoradiation in Non-Small Cell Lung Cancer

Akira Sugimoto,Hiroyasu Kaneda,Naoki Yoshimoto,Kenji Nagata, Tatsuo Fujii, Koichi Michimoto,Shunsuke Ueno,Takao Kamimori, Yoshie Ishii, Mai Sakagami,Haruo Inokuchi,Keiko Shibuya,Megumi Mizutani,Hiroaki Nagamine,Kenji Nakahama,Yoshiya Matsumoto,Yoko Tani,Kenji Sawa,Tomoya Kawaguchi

SCIENTIFIC REPORTSno. 1 (2024)

引用0浏览0WOSNATURE引用

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy in Pulmonary Sarcomatoid Carcinoma

Daisuke Hazama,Kenji Nakahama,Hiroaki Kodama,Akito Miyazaki,Koichi Azuma,Yosuke Kawashima,Yuki Sato,Kentaro Ito,Yoshimasa Shiraishi,Keita Miura,Takayuki Takahama,Satoshi Oizumi,Yoshinobu Namba,Satoshi Ikeda, Hiroshige Yoshioka, Asuka Tsuya,Yuichiro Yasuda,Yoshiki Negi, Ayako Hara,Michihito Toda,Motoko Tachihara

JTO CLINICAL AND RESEARCH REPORTSno. 1 (2024)

引用0浏览0WOS引用

Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data

Kenji Nakahama,Motohiro Izumi,Naoki Yoshimoto,Mitsuru Fukui,Akira Sugimoto,Hiroaki Nagamine,Koichi Ogawa,Kenji Sawa,Yoko Tani,Hiroyasu Kaneda,Shigeki Mitsuoka,Tetsuya Watanabe,Kazuhisa Asai,Tomoya Kawaguchi

ANTICANCER RESEARCHno. 5 (2023): 2185-2197

引用0浏览0WOS引用

RBM17 expression is associated with the efficacy of immune checkpoint inhibitor monotherapy in non-small cell lung cancer with low PD-L1 expression

Hiroaki Nagamine,Masakazu Yashiro,Noriko Yoshimoto,Motohiro Izumi, Akihiro Sugimoto,Kenji Nakahama,Kōichi Ogawa,Yasuyuki Matsumoto, Kôichiro Sawa,Yoko Tani,Hiroyasu Kaneda,Shigeki Mitsuoka, Katsushi Yamada, Tetsu Watanabe,Kazuhisa Aasai,Kazuhiro Fukumura,Akila Mayeda,Tomoya Kawaguchi

Research Square (Research Square) (2023)

引用0浏览0引用

Clinical Significance of KL-6 in Immune-Checkpoint Inhibitor Treatment for Non-Small Cell Lung Cancer

Cancer chemotherapy and pharmacology（2023）

引用0浏览0WOS引用

Vimentin Expression Correlates with Immune Checkpoint Inhibitor Efficacy in Non–small Cell Lung Cancer

Cancerno. 15 (2023): 2297-2307

引用0浏览0WOS引用

P26-9 Clinical Outcome of Nivolumab and Ipilimumab in Untreated Advanced Non-Small Cell Lung Cancer Patients

Akira Sugimoto,Hiroyasu Kaneda,Hiroaki Nagamine,Kenji Nakahama,Koichi Ogawa,Yoshiya Matsumoto,Kenji Sawa,Yoko Tani,Shigeki Mitsuoka,Tatsuo Kimura,Tomoya Kawaguchi

ANNALS OF ONCOLOGY (2023): S1451-S1451

引用0浏览0引用

Tract Creation with a 25-Gauge Needle for Convex Endobronchial Ultrasound-Guided Core Biopsy in Intrapulmonary Lesions Adjacent to Bronchi: Three Case Reports

Hiroaki Nagamine,Toshiyuki Nakai,Takahiro Ueda,Kenji Nakahama,Kenji Sawa,Kazuhiro Yamada,Tetsuya Watanabe,Kazuhisa Aasai,Tomoya Kawaguchi

Translational lung cancer research（2023）

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn